Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision ‐making in otherwise low or intermediate‐1 risk patients with myelofibrosis

Source: British Journal of Haematology - Category: Hematology Authors: Tags: Correspondence Source Type: research
More News: Hematology | UK Health